What's 'Post' About Postgenomic?

   Thursday, Nov 10, 2005 Archives Bio-IT World News Bulletin Subscribe Advertising Your Account  
 

 
 

 
What's 'Post' About Postgenomic?

We've heard the term "postgenomic era" quite a bit over the past half-decade. Despite this, it seems that each week we hear about the publication of the genome of a new species -- a pathogenic microbe, an agricultural staple, or an obscure new species of mammal -- making it hard to imagine finding ourselves in such an era anytime soon. Nevertheless, the technology of sequencing genomes is very late '90s. What is the postgenomic era about? Bioinformatics.


Each of the scores of sequenced genomes comprises thousands of genes that encode an even larger number of proteins and RNAs. Moreover, the expression of each of these genes is regulated by coordinated and combinatorial sets of regulatory elements and factors. It is impractical and improbable that each of the decrypted genes will ever be fully studied in detail. There are just too many. However, this is exactly the sort of challenge that bioinformatics tools can impact.


The analysis of gene expression networks is a case in point. While microarrays allow us to measure gene expression in a massively parallel format, they cannot reveal the molecular mechanisms underlying the dynamic coordination of gene expression. In contrast, in a study* in the July 2005 issue of Trends in Genetics, researchers have shown that comparative genomics can be used to discover new systems of coordinated gene regulation.




 


By comparing 140 sequenced bacterial genomes, the authors uncovered a regulatory system key to bacterial replication. By scanning these genomes, they identified a regulatory sequence involved and the transcription factor that acted through it. They used phylogenetic footprinting to scan the regulatory sequences of genes involved in converting ribonucleotides into deoxyribonucleotides used to replicate DNA. They identified a palindromic sequence that overlapped the promoter region of many of these genes, suggesting it might act as a repressor. They then used phylogenetic profiling to correlate the presence of this sequence in the pertinent genomes with the presence or absence of a protein factor. One protein cluster met the criteria -- and it represented a protein family with characteristics of transcription factors. Using positional clustering -- based on the principle that functionally related genes often inhabit the same genomic neighborhood -- the team found the transcription factor they identified resided close to the genes containing its putative binding sequence. Wet-bench data confirmed the virtual findings.


Prediction and Interaction

Bioinformatics is having an impact on predicting protein structure and function, which is directly relevant to developing therapeutic agents to treat disease. Rutgers University announced a nearly $55-million research effort funded by the Protein Structure Initiative of the National Institute of General Medical Sciences to take a pilot program to develop tools to streamline and speed protein structure prediction to the production phase. Much of the work is based on the wet bench, although clearly it is impractical to crystallize and do detailed structural studies on all members of the proteomes of interest. However, the studies will continue to provide template structures for protein families that should be useful for computer-based structure modeling and drug design. Two hundred structures generated in the pilot studies have provided predictive models for some 40,000 proteins of the 100,000 or so protein families predicted to exist in nature.


A complementary technology that provides information on protein function is interaction mapping analysis, which aims to establish networks of interacting proteins in cells. Hybrigenics is a proteomics services company launched in 2003 that exploits an automated yeast-based two-hybrid process to determine protein interaction. The company identifies interacting partners for a customer's protein(s) of interest, identifies interacting protein domains involved in the interaction, and provides statistical scores to allow the client to evaluate the quality of the results. They also offer a bioinformatics tool called PIM-Rider that allows clients to integrate the data with data available through the Protein Interaction Map. The data will be useful in modeling protein interaction families in related organisms.


Bioinformatics has quickly become an integral part of the drug discovery process. While many algorithms and tools remain open-source and public-domain, it seems only a matter of time before we see a greater number of proprietary services. This will help define the so-called postgenomic era.


Robert M. Frederickson is a biotech writer based in Seattle. E-mail: rfreder@yahoo.com.


*Rodionova, D.A. et al. "Identification of a bacterial regulatory system for ribonucleotide reductases...." Trends Genet 21, 385-9; 2005.



: Featured Events :

Bridging Discovery and IT -September 29 - 30, Philadelphia, PA

4th annual Pharmaceutical Marketing Congress - September 12 - 14, Philadelphia

J. Craig Venter Institute - Genomics, Medicine & the Environment - October 17 - 19, Hilton Head Island, SC

The 2nd Annual Business of Discovery Conference on Molecular Diagnostics Strategic Business Development and Partnerships to Commercialize New Products - October 20 - 21, San Francisco, CA

Would you like to see your conference or event listed here? Contact Shari Redan at
 shari_redan@bio-itworld.com for more information.



: Featured Events :

Upcoming Industry Events

Bridging Discovery and IT - September 29-30, Philadelphia, PA
Bridging Discovery and IT is a unique conference that will highlight novel technologies and strategies that enable organizations to extract knowledge from mountains of heterogeneous data. Drawing on the reputation and expertise of Bio-IT World and Cambridge Healthtech Institute, this conference will feature compelling examples of successful partnerships between IT and biopharma groups and organizations, and insights into cutting-edge information tools and systems. A number of joint presentations from pairs of end users and IT & informatics partners will provide indispensable guidance for surmounting challenges and delivering results. Attendees will gain insights into building a genuine competitive advantage by deriving useful knowledge from data
Find out more at
 www.bridgingdiscoveryandit.com

4th annual Pharmaceutical Marketing Congress - September 12-14, Philadelphia
Attend the Pharmaceutical Marketing Congress and arm yourself with the critical business intelligence you need to communicate the value of your products. Hear P. Roy Vagelos, Former Chairman of the Board and CEO of Merck share his visionary perspectives on our changing industry. Visit
 www.pharmaevent.com for more information.

Genomics, Medicine & the Environment - October 17-19, Hilton Head Island, SC
Enjoy science, sun and sand in beautiful Hilton Head, South Carolina. From nature and medicine to technology and pharmaceutical development, advances in genomic science play a critical role in all areas of life and business. Conference attendees hear first about cutting-edge research, participate in in-depth discussions of future innovations in the field, and have the opportunity to network with other researchers and scientists at the forefront of genomic discovery. The conference will feature three days of ground-breaking science covering relevant topics such as environmental and comparative genomics, genomic medicine, intellectual property rights, the future of genomic testing, and advances in genomic sequencing technologies.
For more information, visit
 http://www.venterinstitute.org/gsac/index.php 

The 2nd Annual Business of Discovery Conference on Molecular Diagnostics Strategic Business Development and Partnerships to Commercialize New Products - October 20-21,San Francisco, CA
https://www.cbinet.com/show_conference.cfm?confCode=HB592 
This conference provides diagnostic and pharmaceutical companies in the molecular diagnostics market space with the latest thinking on issues affecting the development, acceptance and management of genomic based tests for patient care, i.e. assessing the value and clinical utility of tests, patenting of technologies and target molecules, the integration and interpretation of genomic based test results with other tests (imaging, biopsies) for patient care, working with molecular laboratories, pricing and appropriate payment for tests.  Various views and positions on developing and commercializing MDx tests once the genetic discovery work (i.e. biomarker research) has already been done is offered.
For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at
 cbireg@cbinet.com.




This email was delivered to .

To subscribe to Microarray Technology Review, click here.


Published by Bio-IT World Copyright © 2005 Bio-IT World Inc./International Data Group. All rights reserved. No material may be reproduced electronically or in print without written permission from Bio-IT World Inc., One Speen Street, Framingham, MA 01701. For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA; 17601 (717) 399-1900 ext. 172, or email: rwsmith@reprintbuyer.com.